Sarki A Abdulkadir

List of Publications by Year
in descending order

50 papers	2,900 citations	257450 24 h-index	254184 43 g-index
52 all docs	52 docs citations	52 times ranked	4930 citing authors

#	Article	IF	Citations
1	SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress. Cancer Cell, 2010, 17, 41-52.	16.8	705
2	Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell, 2019, 36, 483-497.e15.	16.8	247
3	Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia. Molecular and Cellular Biology, 2002, 22, 1495-1503.	2.3	220
4	Haploinsufficiency at the Nkx3.1 locus. Cancer Cell, 2003, 3, 273-283.	16.8	133
5	Tissue factor expression and angiogenesisin human prostate carcinoma. Human Pathology, 2000, 31, 443-447.	2.0	124
6	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene, 2010, 29, 2477-2487.	5.9	120
7	Targeting FOXA1-mediated repression of TGF-Î² signaling suppresses castration-resistant prostate cancer progression. Journal of Clinical Investigation, 2018, 129, 569-582.	8.2	116
8	Emerging therapeutic targets in bladder cancer. Cancer Treatment Reviews, 2015, 41, 170-178.	7.7	108
9	Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6193-6200.	3.6	79
10	Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Human Pathology, 2014, 45, 1071-1077.	2.0	68
11	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clinical Cancer Research, 2020, 26, 4651-4660.	7.0	68
12	Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Research, 2003, 63, 8079-84.	0.9	68
13	Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nature Communications, 2018, 9, 1591.	12.8	64
14	PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	62
15	Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature Communications, 2020, 11, 4153.	12.8	62
16	Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids. IScience, 2019, 12, 304-317.	4.1	59
17	Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. Journal of Clinical Investigation, 2012, 122, 1907-1919.	8.2	53
18	Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation. Nature Communications, 2016, 7, 12943.	12.8	52

#	Article	IF	Citations
19	EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death and Disease, 2019, 10, 801.	6.3	38
20	Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science Advances, 2021, 7, .	10.3	37
21	Overcoming immunosuppression in bone metastases. Critical Reviews in Oncology/Hematology, 2017, 117, 114-127.	4.4	31
22	Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clinical Cancer Research, 2018, 24, 2732-2739.	7.0	30
23	FIREWORKS: a bottom-up approach to integrative coessentiality network analysis. Life Science Alliance, 2021, 4, e202000882.	2.8	29
24	Association between inflammatory bowel disease and prostate cancer: A largeâ€scale, prospective, populationâ€based study. International Journal of Cancer, 2020, 147, 2735-2742.	5.1	28
25	Haploinsufficient Prostate Tumor Suppression by Nkx3.1. Journal of Biological Chemistry, 2007, 282, 25790-25800.	3.4	27
26	The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer. Journal of the National Cancer Institute, 2019, 111, 311-321.	6.3	27
27	KAT8 Regulates Androgen Signaling in Prostate Cancer Cells. Molecular Endocrinology, 2016, 30, 925-936.	3.7	24
28	Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors. Cancer Research, 2021, 81, 248-253.	0.9	24
29	Activated ALK Cooperates with N-Myc via Wnt/Î²-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 2157-2170.	0.9	24
30	A Functional Variant in <i>NKX3.1</i> Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research, 2014, 7, 950-957.	1.5	22
31	A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression. Science Advances, 2022, 8, eabh3635.	10.3	21
32	Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution. Scientific Reports, 2017, 7, 16285.	3.3	19
33	RNAi Screen Identifies a Synthetic Lethal Interaction between PIM1 Overexpression and PLK1 Inhibition. Clinical Cancer Research, 2014, 20, 3211-3221.	7.0	18
34	Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice. PLoS ONE, 2012, 7, e46792.	2.5	17
35	Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget, 2017, 8, 51264-51276.	1.8	14
36	Macrophages expedite cell proliferation of prostate intraepithelial neoplasia through their downstream target ERK. FEBS Journal, 2021, 288, 1871-1886.	4.7	12

#	Article	IF	Citations
37	Palladium-Catalyzed Coupling Reactions on Functionalized 2-Trifluoromethyl-4-chromenone Scaffolds: Synthesis of Highly Functionalized Trifluoromethyl Heterocycles. Synthesis, 2019, 51, 1342-1352.	2.3	11
38	A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Research, 2022, 82, 2110-2123.	0.9	11
39	Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2â€"ERG fusions. Prostate Cancer and Prostatic Diseases, 2021, 24, 558-566.	3.9	9
40	Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	7
41	A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. Journal of Visualized Experiments, 2018, , .	0.3	6
42	Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome. Frontiers in Oncology, 2019, 9, 77.	2.8	4
43	Advanced glycation endâ€products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry. Prostate, 2021, , .	2.3	1
44	Age-related variation in gene alteration frequency in metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 178-178.	1.6	0
45	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS333-TPS333.	1.6	0
46	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, e17517-e17517.	1.6	0
47	Inhibition of PIM kinase with fractionated radiation and docetaxel in preclinical prostate cancer models.. Journal of Clinical Oncology, 2020, 38, e17534-e17534.	1.6	0
48	A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, TPS274-TPS274.	1.6	0
49	A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 84-84.	1.6	0
50	Development of heterobifunctional proteomimetic polymers for delivery of MYC inhibitory peptides and targeted MYC degradation.. Journal of Clinical Oncology, 2022, 40, e15049-e15049.	1.6	0